Inactive Instrument

Sanofi SA Stock Nyse

Equities

US80105N1054

Pharmaceuticals

Sales 2024 * 46.36B 49.64B Sales 2025 * 49.73B 53.25B Capitalization 111B 119B
Net income 2024 * 7.34B 7.87B Net income 2025 * 8.62B 9.23B EV / Sales 2024 * 2.54 x
Net Debt 2024 * 6.89B 7.38B Net Debt 2025 * 2.7B 2.89B EV / Sales 2025 * 2.29 x
P/E ratio 2024 *
15.1 x
P/E ratio 2025 *
12.9 x
Employees -
Yield 2024 *
4.3%
Yield 2025 *
4.65%
Free-Float 87.01%
More Fundamentals * Assessed data
Dynamic Chart
Managers TitleAgeSince
Chief Executive Officer 56 19-08-31
Chief Operating Officer 39 21-12-31
Chief Tech/Sci/R&D Officer 51 -
Members of the board TitleAgeSince
Director/Board Member 70 14-04-30
Director/Board Member 64 20-05-21
Director/Board Member 52 20-04-27
More insiders
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (70.6%): prescription drugs in the areas of specialty medicine (59.3% of net sales; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune diseases, rare diseases, cancers and rare hematological diseases) and general medicine (40.7%; mainly for the treatment of diabetes and cardiovascular diseases); - human vaccines (17.4%): pediatric vaccines, vaccines for flu, meningitis, and polio, booster vaccines, and vaccines for travelers and endemic areas; - consumer health products (12%). At the end of 2023, the group had 54 production sites throughout the world. Net sales are distributed geographically as follows: France (5.5%), Europe (18.6%), the United States (43%), North America (1.6%) and other (31.3%).
Calendar
More about the company